Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide
Tóm tắt
Từ khóa
Tài liệu tham khảo
Morris, 1995, New immunosuppressive drugs, 760
Morris, 1996, Mechanism of action of new immunosuppressive drugs, Kidney Int Suppl, 49, S26
Goto, 1987, Discovery of FK-506, a novel immunosuppressant isolated from Streptomyces tsukubaensis, Transplant Proc, 19, 4
Ochiai, 1987, Effect of a new immunosuppressive agent, FK 506, on heterotopic cardiac allotransplantation in the rat, Transplant Proc, 19, 1284
Griffith, 1995, X-ray structure of calcineurin inhibited by the immunophilin-immunosuppressant FKBP12-FK506 complex, Cell, 82, 507, 10.1016/0092-8674(95)90439-5
Kissinger, 1995, Crystal structures of human calcineurin and the human FKBP12-FK506-calcineurin complex, Nature, 378, 641, 10.1038/378641a0
Loh, 1996, Calcineurin binds the transcription factor NFAT1 and reversibly regulates its activity, J Biol Chem, 271, 10884, 10.1074/jbc.271.18.10884
Cardenas, 1995, Targets of immunophilin-immunosuppressant complexes are distinct highly conserved regions of calcineurin A, EMBO J, 14, 2772, 10.1002/j.1460-2075.1995.tb07277.x
Lam, 1995, A novel FK506 binding protein can mediate the immunosuppressive effects of FK506 and is associated with the cardiac ryanodine receptor, J Biol Chem, 270, 26511, 10.1074/jbc.270.44.26511
Cameron, 1995, Calcineurin associated with the inositol 1,4,5-triphosphate receptor-FKBP12 complex modulates Ca2+ flux, Cell, 83, 463, 10.1016/0092-8674(95)90124-8
Baughman, 1995, FKBP51, a novel T-cell-specific immunophilin capable of calcineurin inhibition, Mol Cell Biol, 15, 4395, 10.1128/MCB.15.8.4395
Bennett, 1995, The nephrotoxicity of immunosuppressive drugs, Clin Nephrol, 43, 3
Goodall, 1995, FK506-induced endothelin release by cultured rat mesangial cells, J Cardiovasc Pharmacol, 26, 482, 10.1097/00005344-199506263-00142
Andoh, 1995, Functional and structural characteristics of experimental FK 506 nephrotoxicity, Clin Exp Pharmacol Physiol, 22, 646, 10.1111/j.1440-1681.1995.tb02082.x
Hadad, 1995, FK 506: effects on glomerular hemodynamics and on mesangial cells in culture, Kidney Int, 48, 56, 10.1038/ki.1995.267
Muraoka, 1996, Immunosuppressant FK506 induces interleukin-6 production through the activation of transcription factor nuclear factor (NF)-kB, J Clin Invest, 97, 2433, 10.1172/JCI118690
Calne, 1989, Rapamycin for immunosuppression in organ allografting [letter], Lancet, 2, 227, 10.1016/S0140-6736(89)90417-0
Morris, 1989, Identification of a new pharmacologic action for an old compound, Med Sci Res, 17, 609
Morris, 1991, Repamycin: FK506's fraternal twin or distant cousin?, Immunol Today, 12, 137, 10.1016/S0167-5699(05)80040-4
Morris, 1992, Rapamycin: antifungal, antitumor antiproliferative, and immunosuppressive macrolides, Transplant Rev, 6, 39, 10.1016/S0955-470X(10)80014-X
Sehgal, 1995, Rapamycin (sirolimus, rapamune), Curr Opin Nephrol Hypertens, 4, 482, 10.1097/00041552-199511000-00004
Lorenz, 1995, TOR mutations confer rapamycin resistance by preventing interaction with FKBP12-rapamycin, J Biol Chem, 270, 27531, 10.1074/jbc.270.46.27531
Zheng, 1995, TOR kinase domains are required for two distinct functions, only one of which is inhibited by rapamycin, Cell, 82, 121, 10.1016/0092-8674(95)90058-6
Sabers, 1995, Isolation of a protein target of the FKBP12—rapamycin complex in mammalian cells, J Biol Chem, 270, 815, 10.1074/jbc.270.2.815
Chen, 1995, Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue, Proc Natl Acad Sci USA, 92, 4947, 10.1073/pnas.92.11.4947
Sabatini, 1995, The rapamycin and FKBP12 target (RAFT) displays phosphatidylinositol 4-kinase activity, J Biol Chem, 270, 20875, 10.1074/jbc.270.36.20875
Choi, 1996, Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP, Science, 273, 239, 10.1126/science.273.5272.239
Terada, 1995, Rapamycin inhibits ribosomal protein synthesis and induces G1 prolongation in mitogen-activated T lymphocytes, J Immunol, 155, 3418, 10.4049/jimmunol.155.7.3418
Mahalingam, 1996, Constitutive activation of S6 kinase by deletion of amino-terminal autoinhibitory and rapamycin sensitivity domains, Mol Cell Biol, 16, 405, 10.1128/MCB.16.1.405
Pearson, 1995, The principal target of rapamycin-induced p70s6K inactivation is a novel phosphorylation site within a conserved hydrophobic domain, EMBO J, 14, 5279, 10.1002/j.1460-2075.1995.tb00212.x
Feuerstein, 1995, Rapamycin selectively blocks interleukin-2-induced proliferating cell nuclear antigen gene expression in T lymphocyte. Evidence for inhibition of CREB/ATF binding activities, J Biol Chem, 270, 9454, 10.1074/jbc.270.16.9454
Gregory, 1995, Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement, Transplantation, 59, 655, 10.1097/00007890-199503150-00002
Morris, 1995, Rapamycin (sirolimus) inhibits vascular smooth muscle DNA synthesis in vitro and suppresses narrowing in arterial allografts and in balloon-injured carotid arteries: evidence that rapamycin antagonizes growth factor action on immune and nonimmune cells, Transplant Proc, 27, 430
Cao, 1995, Effects of rapamycin on growth factor-stimulated vascular smooth muscle cell DNA synthesis. Inhibition of basic fibroblast growth factor and platelet-derived growth factor action and antagonism of rapamycin by FK506, Transplantation, 59, 390, 10.1097/00007890-199502150-00014
Marx, 1995, Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells, Circ Res, 76, 412, 10.1161/01.RES.76.3.412
Ransom, 1995, Mechanism of action of mycophenolate mofetil, Ther Drug Monit, 17, 681, 10.1097/00007691-199512000-00023
Wu, 1994, Mycophenolate mofetil: molecular mechanisms of action, Perspect Drug Discovery Res, 2, 185, 10.1007/BF02171743
Morris, 1995, New immunosuppressive drugs: mycophenolate mofetil, New Dev Transplant Med, 2, 10
Laurent, 1996, Mycophenolic acid suppresses protein N-linked glycosylation in human monocytes and their adhesion to endothelial cells and to some substrates, Exp Hematol, 24, 59
Morris, 1989, Prolongation of rat heart allograft survival by RS-61443, Surg Forum, 40, 337
Kimball, 1995, Reduced human IgG anti-ATGAM antibody formation in renal transplant recipient receiving mycophenolate mofetil, Transplantation, 60, 1379, 10.1097/00007890-199560120-00001
Fraser-Smith, 1995, Suppression by mycophenolate mofetil of the neointimal thickening caused by vascular injury in a rat arterial stenosis model, J Pharmacol Exp Ther, 275, 1204
Hager, 1995, Recombinant human inosine monophosphate dehydrogenase type I and type II proteins. Purification and characterization of inhibitor binding, Biochem Pharmacol, 49, 1323, 10.1016/0006-2952(95)00026-V
Makara, 1996, Nuclear magnetic resonance and molecular modeling study on mycophenolic acid: implications for binding to inosine monophosphate dehydrogenase, J Med Chem, 39, 1236, 10.1021/jm950600m
Langman, 1996, Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression by measurement of inosine monophosphate dehydrogenase activity in a canine model, Transplantation, 61, 87, 10.1097/00007890-199601150-00018
Langman, 1996, Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression by measurement of inosine monophosphate dehydrogenase activity in a canine model, Transplantation, 61, 87, 10.1097/00007890-199601150-00018
Allison, 1994, Preferential suppresion of lymphocyte proliferation by mycophenolic acid and predicted long-term effects of mycophenolate mofetil in transplantation, Transplant Proc, 26, 3205
Catapano, 1995, GTP depletion induced by IMP dehydrogenase inhibitors blocks RNa-primed DNA synthesis, Mol Pharmacol, 47, 948
Senda, 1995, Mycophenolic acid, an inhibitor of IMP dehydrogenase that is also an immunosuppressive agent, suppresses the cytokine-induced nitric oxide production in mouse and rat vascular endothelial cells, Transplantation, 60, 1143, 10.1097/00007890-199511270-00015
Sollinger, 1995, Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients, Transplantation, 60, 225, 10.1097/00007890-199508000-00003
1995, Placebo-controlled study of mycophenolate mofetil combined with combined with cyclosporin and corticosteroids for the prevention of acute rejection, Lancet, 345, 1321, 10.1016/S0140-6736(95)92534-1
Cherwinski, 1995, The immunosuppressant leflunomide inhibits lymphocyte progression through cell cycle by a novel mechanism, J Pharmacol Exp Ther, 272, 460
Bartlett, 1994, Leflunomide: a novel immunomodulating drug, 349
Siemasko, 1996, Regulation of B cell function by the immunosuppressive agent leflunomide, Transplantation, 61, 635, 10.1097/00007890-199602270-00020
Morris, 1995, Transplant Proc, 27, 445
Cao, 1995, Mechanism of the antiproliferative action of leflunomide, J Heart Lung Transplant, 14, 1016
Morris, 1995, Studies in experimental models of chronic rejection: use of rapamycin (sirolimus) and isoxazole derivatives (leflunomide and its analog) for the suppression of graft vascular disease and obliterative bronchiolitis, Transplant Proc, 27, 2068
Nair, 1996, The antiproliferative effects of leflunomide on vascular smooth muscle cells in vitro is mediated by selective inhibition of pyrimidine synthesis, Transplant Proc
Mladenovic, 1995, Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II study, Arthritis Rheum, 38, 1595, 10.1002/art.1780381111
Williamson, 1995, Dihydroorotate dehydrogenase is a high affinity binding protein for A77 1726 and mediator of a range of biological effects of the immunomodulatory compound, J Biol Chem, 270, 22467, 10.1074/jbc.270.38.22467
Cao, 1996, A novel mechanism of action of the immunomodulatory drug leflunomide: augmentation of the immunosuppressive cytokine TGF-β1 and suppression of the immunostimulatory cytokine IL-2, Transplant Proc
Lang, 1995, Differential effects of the immunosuppressive agents cyclosporine and leflunomide in vivo. Leflunomide blocks clonal T cell expansion yet allows production of lymphokines and manifestation of T cell mediated shock, Transplantation, 59, 382, 10.1097/00007890-199502150-00013
Zielinski, 1995, Leflunomide, a reversible inhibitor of pyrimidine biosynthesis?, Inflamm Res, 44, 207, 10.1007/BF01778336
Xu, 1995, Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomide, J Biol Chem, 270, 12398, 10.1074/jbc.270.21.12398
Nikcevich, 1994, Inhibition of interleukin 2-stimulated tyrosine kinase activity by leflunomide, Agents Actions, 41, 279, 10.1007/BF01987669
Chong, 1996, Effects of leflunomide and other immunosuppressive agents on T cell proliferation in vitro, Transplantation, 61, 140, 10.1097/00007890-199601150-00026
Silva, 1996, Mechanism of action of leflunomide in vivo uridine administration reverses LFM's inhibition of lymphocyte proliferation, Transplant Proc
Greene, 1995, Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide, Biochem Pharmacol, 50, 861, 10.1016/0006-2952(95)00255-X
Davis, 1996, The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorolate dehydrogenase, Biochemistry, 35, 1270, 10.1021/bi952168g
Cherwinski, 1995, Leflunomide interferes with pyrimidine nucleotide biosynthesis, Inflamm Res, 44, 317, 10.1007/BF01796261
Cherwinski, 1995, Leflunomide interferes with pyrimidine nucleotide biosynthesis, Inflamm Res, 44, 317, 10.1007/BF01796261
Peters, 1983, Purine and pyrimidine metabolism in peripheral blood lymphocytes, Int J Biochem, 15, 115, 10.1016/0020-711X(83)90051-4